The US Food and Drug Administration (FDA) is investigating whether chimeric antigen receptor (CAR) T-cell immunotherapies can cause secondary blood cancers. Secondary cancers are a known […]

The US Food and Drug Administration (FDA) approved a new colony-stimulating factor, efbemalenograstim alfa (Ryzneuta, Evive Biotech), to decrease the incidence of infection, as manifested by […]

The US Food and Drug Administration approved nirogacestat (Ogsiveo, SpringWorks Therapeutics, Inc) to treat progressive, unresectable, recurrent, or refractory desmoid tumors in adults. Nirogacestat, an oral […]

The US Food and Drug Administration (FDA) has approved enzalutamide (Xtandi, Astellas and Pfizer) for men with nonmetastatic castration-sensitive prostate cancer who experience biochemical recurrence and […]

The US Food and Drug Administration (FDA) has approved the immune checkpoint inhibitor pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of adult […]

The US Food and Drug Administration (FDA) has approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for certain previously treated adults with hormone receptor (HR)–positive, human epidermal […]

The US Food and Drug Administration (FDA) has approved repotrectinib (Augtyro, Bristol Myers Squibb) for adults with locally advanced or metastatic ROS1-postive non–small cell lung cancer […]